The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
The increase includes greater spending on Alzheimer's disease research, precision medicine, and cancer research initiatives.
Entering a new chapter with a new leader, ACLA lends support to a draft bill that would regulate lab tests not as medical devices but as in vitro clinical tests.
With data analytics and more specific billing codes, the government has improved its ability to identify medically unnecessary genetic testing and other fraudulent activity.
The company beat the consensus Wall Street estimates on both the top and bottom lines. It also increased its EPS outlook for full-year 2017.
S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.
The agency said it is giving labs 60 additional days to report private payor rates but is still expecting to launch the new clinical lab fee schedule in 2018.
ACLA said the goal of the delay is to redefine "applicable laboratories" and give labs and CMS more time to collect data that will inform market-based pricing.
Centers for Medicare & Medicaid Services pick Seema Verma has been confirmed, the Wall Street Journal reports.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.